| Hypertensive disease
Inderal LA vs Katerzia
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Inderal vs Katerzia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKaterzia has a higher rate of injection site reactions vs Inderal based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Katerzia but not Inderal, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inderal
Katerzia
At A Glance
Oral
Once daily
Nonselective beta-blocker
Oral
Daily
Calcium channel blocker
Indications
- Hypertensive disease
- Coronary Arteriosclerosis
- Migraine Disorders
- Idiopathic hypertrophic subaortic stenosis
- Hypertensive disease
- Stable angina
- Angina Pectoris, Variant
- Coronary Artery Disease
Dosing
Hypertensive disease Initial 80 mg once daily; may increase to 120 mg or higher; usual maintenance 120-160 mg once daily; up to 640 mg may be required.
Coronary Arteriosclerosis Start 80 mg once daily; increase at 3-7 day intervals; average optimal dose 160 mg once daily; maximum established dose 320 mg once daily.
Migraine Disorders Initial 80 mg once daily; usual effective range 160-240 mg once daily; discontinue if no response within 4-6 weeks at maximal dose.
Idiopathic hypertrophic subaortic stenosis Usual dosage 80-160 mg once daily.
Hypertensive disease (adults) 5 mg orally once daily (max 10 mg); start 2.5 mg in small, fragile, elderly patients, or those with hepatic insufficiency.
Hypertensive disease (pediatric, ages 6-17) 2.5-5 mg orally once daily; doses >5 mg have not been studied in pediatric patients.
Stable angina, Angina Pectoris, Variant 5-10 mg orally once daily; lower dose suggested in elderly and patients with hepatic insufficiency; most patients require 10 mg.
Coronary Artery Disease 5-10 mg orally once daily; majority of patients required 10 mg in clinical studies.
Contraindications
- Cardiogenic shock
- Sinus bradycardia and greater than first-degree block
- Bronchial asthma
- Known hypersensitivity to propranolol hydrochloride
- Known sensitivity to amlodipine
Adverse Reactions
Cardiovascular Bradycardia, congestive heart failure, intensification of AV block, hypotension, paresthesia of hands, thrombocytopenic purpura, arterial insufficiency (Raynaud type)
Central Nervous System Light-headedness, mental depression, insomnia, lassitude, weakness, fatigue, catatonia, visual disturbances, hallucinations, vivid dreams, disorientation, short-term memory loss, emotional lability
Gastrointestinal Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis
Allergic Hypersensitivity reactions including anaphylactic/anaphylactoid reactions, pharyngitis, agranulocytosis, erythematous rash, fever with aching and sore throat, laryngospasm, respiratory distress
Respiratory Bronchospasm
Hematologic Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura
Autoimmune Systemic lupus erythematosus
Skin and Mucous Membranes Stevens-Johnson Syndrome, toxic epidermal necrolysis, dry eyes, exfoliative dermatitis, erythema multiforme, urticaria, alopecia, SLE-like reactions, psoriasisiform rashes
Genitourinary Male impotence, Peyronie's disease
Most common (>1%) edema, dizziness, flushing, palpitation, fatigue, nausea, abdominal pain, somnolence
Postmarketing gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder
Pharmacology
Propranolol is a nonselective beta-adrenergic receptor-blocking agent that competitively blocks beta-receptor-stimulating agents, reducing chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation; at doses greater than required for beta blockade, it also exerts a quinidine-like membrane action affecting the cardiac action potential.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation, reduction in peripheral vascular resistance, and reduction in blood pressure.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inderal
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (5/12)
Katerzia
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (8/12)
UnitedHealthcare
Inderal
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Katerzia
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Inderal
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Katerzia
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Inderal.
No savings programs available for Katerzia.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InderalView full Inderal profile
KaterziaView full Katerzia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.